topic

1184 A platform for tuning therapeutic efficacy of T-Cell-engaging bispecific antibodies
Jane Seagal, Arvin Akoopie, Alireza Ataei, Dana Duey, Olena Gorbenko, Ranveer Jayani, Fiana Levitin, Oscar Martinez, Shaden Omar, Ritsuko Sawada, Jonah Rainey

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A1305; DOI: 10.1136/jitc-2023-SITC2023.1184
1186 Engineering bispecific dual-antagonist antibodies for novel cancer therapies
Ankita Srivastava, Tracy Charlton, Ranveer Jayani, Omer Keinan, Arvin Akoopie, Jonah Rainey, Jacek Ostrowski

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A1306; DOI: 10.1136/jitc-2023-SITC2023.1186
1187 Antibody-lectin bispecifics for glyco-immune checkpoint blockade
Jessica Stark, Melissa Gray, Simon Wisnovsky, Itziar Ibarlucea-Benitez, Nicholas Riley, Mikaela Ribi, Marta Lustig, Wesley Errington, Bence Bruncsics, Casim Sarkar, Thomas Valerius, Jeffrey Ravetch, Carolyn R Bertozzi

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A1307; DOI: 10.1136/jitc-2023-SITC2023.1187
1188 In vitro and in vivo characterization of CD8⁺ T cell engagers (TCEs) for cancer immunotherapy
Guiyun Tu, Wuzhong Shen, Zheng Yang, Shengjie Xue, Ying Tan, Bingbin Xie, Ke Wang, Zhejin Zhang, Su He, Zuowen Duan, Linsen Gao, Bin Xie, Hanyang Chen, Xiaoqiang Yan

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A1308; DOI: 10.1136/jitc-2023-SITC2023.1188
1189 Elucidating the effects of chemotherapy and immune checkpoint blockade on the activity of tarlatamab, a DLL3-targeting bispecific T cell engager molecule, in small cell lung cancer preclinical models
Ran You, Juan Estrada, Jinghui Zhan, Petra Deegen, Keegan Cooke, Matthias Friedrich, Julie M Bailis

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A1309; DOI: 10.1136/jitc-2023-SITC2023.1189
1190 A novel ‘2+1’bispecific T cell engager platform, enables enhanced anti-tumor activity with reduced risk of CRS
Hui Yuwen, Tengteng Li, Yijing Ren, Jay Mei, Bo Shan, Bing Hou

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A1310-A1311; DOI: 10.1136/jitc-2023-SITC2023.1190
1191 ATG-021, a novel 2+1 CD3-based T cell engager (TCE) targeting GPRC5D, demonstrates potent in vivo anti-tumor efficacy with low cytokine release
Hui Yuwen, Tengteng Li, Yijing Ren, Jay Mei, Bo Shan, Bing Hou

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A1312-A1313; DOI: 10.1136/jitc-2023-SITC2023.1191
1192 A novel MSLN×4–1BB bispecific antibody for solid tumor
Dayan Zhang, Wenting Liu, Guodong Shen, Weiming Zhou, Xiaoli Zeng, Liansheng Cheng

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A1314; DOI: 10.1136/jitc-2023-SITC2023.1192
1193 Synergistic targeting of multiple activating pathways with natural killer cell engagers
Tian Zhang, Matthew S Faber, Erik Pong, Ke Liu, Nahee Kim, Matthew J Bernett, Christine Bonzon, James Wieler, Juan E Diaz, Kendra N Avery, Elizabeth Henderson, William Y Yeh, Jing Qi, Su-Shin Hao, Rumana Rashid, Rena Bahjat, John R Desjarlais, Katrina Bykova

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A1315; DOI: 10.1136/jitc-2023-SITC2023.1193
1194 Mechanism of action of ivonescimab (AK112/SMT112): a first-in-class tetravalent Fc-silent bispecific antibody with dual blockade of PD-1 and VEGF that promotes cooperative biological effects
Tingting Zhong, Zhaoliang Huang, Xinghua Pang, Chunshan Jin, Xinrong He, Jose Montoya, Betty Chang, Michelle Xia, Baiyong Li, Jing Min

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A1316-A1317; DOI: 10.1136/jitc-2023-SITC2023.1194

Main menu

topic

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

topic

Pages